According to a study published in August 2026 in the journal Nature, scientists at the Shanghai Academy of Natural Sciences developed an oral living drug called GIFT, which uses engineered probiotic bacteria to sense rising blood sugar levels and automatically release the hormone GLP-1. This smart delivery system aims to replace traditional, fixed-dose diabetes injections with an on-demand mechanism that activates only when glucose concentrations spike in the intestine.
How the GIFT Probiotic System Detects Blood Sugar Spikes
Researchers built a synthetic glucose-sensing genetic switch inside a harmless strain of gut bacteria called Escherichia coli Nissle 1917, or EcN, according to the Nature study. Under normal conditions, a protein known as HexR binds to a promoter region to keep therapeutic genes inactive. When a person eats high-sugar foods, the bacterial metabolism converts the incoming glucose into a molecule called KDPG. This molecule binds to HexR and forces it to detach from the promoter, signaling the bacteria to produce and release GLP-1. To survive the harsh environment of the gastrointestinal tract, the team coated the bacteria with FDA-approved materials, specifically tannic acid and poloxamer 188. This protective coating extended the active lifespan of the bacteria in mouse intestines from eight hours up to thirty-six hours.
Results in Diabetic Mice and Nonhuman Primates
Experiments on animal models demonstrated that the living drug can successfully lower blood glucose without constant user intervention. When diabetic mice received the GIFT treatment, the probiotic sensed elevated blood sugar thresholds and responded by secreting GLP-1, which triggered insulin release and automatically shut off once levels returned to normal ranges. According to the research findings, thirty days of daily treatment reduced fat mass, weight gain, triglycerides, and total cholesterol in mice while protecting liver and kidney health. When tested on naturally diabetic monkeys—chosen because their genetics closely mirror humans—a single oral dose of the probiotic boosted insulin and regulated blood sugar for up to three days.
Did you know? Unlike traditional subcutaneous diabetes drugs that circulate a constant dose throughout the body, the GIFT probiotic restricts hormone production strictly to the gut lumen, reducing systemic side effects.
Comparing GIFT to Traditional GLP-1 Receptor Agonists
The research team directly compared their probiotic treatment against semaglutide, a widely used injectable GLP-1 receptor agonist. While semaglutide delivers a constant high dose of medicine, the smart probiotic responds dynamically to real-time metabolic needs. According to the study data, mice treated with semaglutide lost lean muscle tissue over a two-month period, whereas mice given the probiotic preserved or slightly increased their lean muscle mass. Additionally, the probiotic reduced the risk of hypoglycemia when combined with insulin therapy.
Path to Clinical Trials and Future Regulation
Moving from animal studies to human application requires navigating significant regulatory hurdles. Because the therapy relies on a genetically modified organism, the treatment must undergo rigorous safety trials and stability testing before receiving approval for clinical use. Researchers state that these next phases are essential to determine whether the oral living drug can safely replicate its precise, self-regulating glycemic control in human patients.
Frequently Asked Questions
What is the GIFT system?
GIFT is an oral living drug made from engineered probiotic bacteria designed to sense high blood sugar and release GLP-1 on demand.
How do the probiotics survive in the gut?
Researchers coat the bacteria with FDA-approved tannic acid and poloxamer 188, which protects them and extends their active lifespan in the intestines.
How does GIFT compare to semaglutide?
While semaglutide delivers a constant systemic dose and can lead to lean muscle loss over time, animal studies suggest GIFT preserves muscle mass and releases medicine only when blood sugar rises.
What are the next steps for this research?
The therapy must undergo comprehensive safety trials, stability testing, and regulatory reviews before it can be approved for human clinical use.
If you found this reporting helpful, consider subscribing to our newsletter or sharing this article with your community to support independent science journalism.
Worth a look